Goodwood buying at Pediapharm (PDP)

Goodwood buying at Pediapharm (:PDP)

Goodwood Inc., a 10% Holder, acquired 938,235 Common Shares on a control or direction basis for registered holder A fund managed by Goodwood Inc. through a prospectus or prospectus exempt offering on October 16th, 2018. The insider also acquired 469,117 Warrants with an exercise price of $0.630 through a prospectus or prospectus exempt offering on October 16th, 2023. This represents a $1,477,560 net investment into the company's shares and an account share holdings change of greater than 100%.

Pediapharm is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Pediapharm Inc. (Pediapharm) is a specialty pharmaceutical company. The Company distributes prescription medicines used to treat pathological conditions that mainly affect children from infancy to 18 years of age. The Company sells products and offers marketing services to the pharmaceutical industry, particularly related to pediatric care. It offers NYDA, a treatment indicated for eradication of head lice and its eggs. The products that the Company distributes originate from transactions whereby Pediapharm acquires intellectual property rights through a licensing agreement that enables Pediapharm to register the drug products with Health Canada in order to commercialize them. Pediapharm does not produce, manufacture or develop products, but rather licenses finished products and sells them. Pediapharm also commercializes non-prescription products (non-prescription drugs, medical devices, diagnostic products). The Company's subsidiary is Pediapharm Licensing Inc.